These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33461367)

  • 1. The 3-Item "Apathy" Subscale Within the GDS-15 Is Not Supported in De Novo Parkinson's Disease Patients: Analysis of the PPMI Cohort.
    Szymkowicz SM; Ellis LJ; May PE
    J Geriatr Psychiatry Neurol; 2022 May; 35(3):309-316. PubMed ID: 33461367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the Geriatric Depression Scale measure depression in Parkinson's disease?
    Lopez FV; Split M; Filoteo JV; Litvan I; Moore RC; Pirogovsky-Turk E; Liu L; Lessig S; Schiehser DM
    Int J Geriatr Psychiatry; 2018 Dec; 33(12):1662-1670. PubMed ID: 30251374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometric properties of the apathy evaluation scale in patients with Parkinson's disease.
    Lueken U; Evens R; Balzer-Geldsetzer M; Baudrexel S; Dodel R; Gräber-Sultan S; Hilker-Roggendorf R; Kalbe E; Kaut O; Mollenhauer B; Reetz K; Schäffer E; Schmidt N; Schulz JB; Spottke A; Witt K; Linse K; Storch A; Riedel O
    Int J Methods Psychiatr Res; 2017 Dec; 26(4):. PubMed ID: 28418163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal decline in striatal dopamine transporter binding in Parkinson's disease: associations with apathy and anhedonia.
    Costello H; Yamamori Y; Reeves S; Schrag AE; Howard R; Roiser JP
    J Neurol Neurosurg Psychiatry; 2023 Oct; 94(10):863-870. PubMed ID: 37221053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apathy in elderly nondemented patients with Parkinson's disease: clinical determinants and relationship to quality of life.
    Skorvanek M; Rosenberger J; Gdovinova Z; Nagyova I; Saeedian RG; Groothoff JW; Dijk JP
    J Geriatr Psychiatry Neurol; 2013 Dec; 26(4):237-43. PubMed ID: 23970460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between Apathy and Subjective Poor Night-time Sleep in de novo, Untreated Parkinson's Disease.
    Hong CM; Kim DH; Ahn BC; Seo JG; Ryu HS
    J Integr Neurosci; 2022 Apr; 21(3):74. PubMed ID: 35633155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease.
    Espay AJ; Foster ED; Coffey CS; Uribe L; Caspell-Garcia CJ; Weintraub D;
    J Neurol Sci; 2019 Jul; 402():81-85. PubMed ID: 31125734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the Unified Parkinson's Disease Rating Scale (UPDRS) section I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease.
    Pedersen KF; Larsen JP; Aarsland D
    Parkinsonism Relat Disord; 2008; 14(3):183-6. PubMed ID: 17889589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
    Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
    Zitser J; Peretz C; Ber David A; Shabtai H; Ezra A; Kestenbaum M; Brozgol M; Rosenberg A; Herman T; Balash Y; Gadoth A; Thaler A; Stebbins GT; Goetz CG; Tilley BC; Luo ST; Liu Y; Giladi N; Gurevich T
    Parkinsonism Relat Disord; 2017 Dec; 45():7-12. PubMed ID: 28965872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatigue in de novo Parkinson's Disease: Expanding the Neuropsychiatric Triad?
    Béreau M; Castrioto A; Lhommée E; Maillet A; Gérazime A; Bichon A; Pélissier P; Schmitt E; Klinger H; Longato N; Fraix V; Benatru I; Durif F; Azulay JP; Moro E; Broussolle E; Tranchant C; Anheim M; Thobois S; Krack P
    J Parkinsons Dis; 2022; 12(4):1329-1337. PubMed ID: 35253781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Change and Progression Indicators Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale in Two Independent Cohorts with Early Parkinson's Disease.
    Bartl M; Dakna M; Schade S; Wicke T; Lang E; Ebentheuer J; Weber S; Trenkwalder C; Mollenhauer B
    J Parkinsons Dis; 2022; 12(1):437-452. PubMed ID: 34719511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations.
    Leentjens AF; Dujardin K; Marsh L; Martinez-Martin P; Richard IH; Starkstein SE; Weintraub D; Sampaio C; Poewe W; Rascol O; Stebbins GT; Goetz CG
    Mov Disord; 2008 Oct; 23(14):2004-14. PubMed ID: 18709683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imbalanced motivated behaviors according to motor sign asymmetry in drug-naïve Parkinson's disease.
    Béreau M; Castrioto A; Servant M; Lhommée E; Desmarets M; Bichon A; Pélissier P; Schmitt E; Klinger H; Longato N; Phillipps C; Wirth T; Fraix V; Benatru I; Durif F; Azulay JP; Moro E; Broussolle E; Thobois S; Tranchant C; Krack P; Anheim M
    Sci Rep; 2023 Dec; 13(1):21234. PubMed ID: 38040775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apathy and Anxiety in De Novo Parkinson's Disease Predict the Severity of Motor Complications.
    Hinkle JT; Perepezko K; Gonzalez LL; Mills KA; Pontone GM
    Mov Disord Clin Pract; 2021 Jan; 8(1):76-84. PubMed ID: 33426161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
    Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
    J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort.
    Holden SK; Finseth T; Sillau SH; Berman BD
    Mov Disord Clin Pract; 2018; 5(1):47-53. PubMed ID: 29662921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deconstructing Apathy in Parkinson's Disease: Challenges in Isolating Core Components of Apathy From Depression, Anxiety, and Fatigue.
    Ineichen C; Baumann-Vogel H
    Front Neurol; 2021; 12():720921. PubMed ID: 34512530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.